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Abstract
Purpose: The optimal treatment duration for ventilator-associated pneumonia is based on one study dealing with late-
onset of the condition. Shortening the length of antibiotic treatment remains a major prevention factor for the emergence
of multiresistant bacteria.
Objective: To demonstrate that 2 different antibiotic treatment durations (8 versus 15 days) are equivalent in terms of
clinical cure for early-onset ventilator-associated pneumonia.
Methods: Randomized, prospective, open, multicenter trial carried out from 1998 to 2002.
Measurements: The primary endpoint was the clinical cure rate at day 21. The mortality rate was evaluated on days 21 and
90.
Results: 225 patients were included in 13 centers. 191 (84.9%) patients were cured: 92 out of 109 (84.4%) in the 15 day
cohort and 99 out of 116 (85.3%) in the 8 day cohort (difference = 0.9%, odds ratio = 0.929). 95% two-sided confidence
intervals for difference and odds ratio were [28.4% to 10.3%] and [0.448 to 1.928] respectively. Taking into account the
limits of equivalence (10% for difference and 2.25 for odds ratio), the objective of demonstrative equivalence between the 2
treatment durations was fulfilled. Although the rate of secondary infection was greater in the 8 day than the 15 day cohort,
the number of days of antibiotic treatment remained lower in the 8 day cohort. There was no difference in mortality rate
between the 2 groups on days 21 and 90.
Conclusion: Our results suggest that an 8-day course of antibiotic therapy is safe for early-onset ventilator-associated
pneumonia in intubated patients.
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Introduction
Pneumonia is the second-most-common nosocomial infection
and accounts for around 15% of infections acquired in hospitals.
The incidence rate varies from 1% in medical departments to 20%
in intensive care units (ICU!) [1]. Intubation and mechanical
ventilation (MV) are known risk factors for the acquisition of
nosocomial pneumonia [2]. Ventilator-associated pneumonia
(VAP) is a common, serious condition and therefore poses a real
public health problem, particularly in ICU where the mortality
rate for ventilated patients lies above 50% [3,4]. VAP is defined as
having either an early- or a late-onset according to whether it
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begins before or after the first 5 to 7 days of hospitalization [4].
During early-onset ventilator-associated pneumonia (EOVAP), the
normal bacterial flora consists of Haemophilus influenzae, Streptococcus
pneumoniae, methicillin-sensitive Staphylococcus aureus, Moraxella catar-
rhalis and non multiresistant Escherichia coli [5,6]. The bacteria
isolated may vary due to antibiotic treatment, recent hospitaliza-
tion and ICU ecology [7,8,9,10]. Several recent studies have
evaluated the impact of antibiotic treatment duration on clinical
cure and recurrence rates. In a randomized prospective study,
Chastre et al. found no clear advantage in prolonging antibiotic
treatment to 15 days compared with 8 days when treating late-
onset VAP [11]. Other authors [12,13,14] have evaluated the use
of clinical scores (CPIS) and biological markers (Procalcitonin -
PCT) for reducing treatment duration [15]. Resolution of
infectious parameters after appropriate antibiotic treatment occurs
within 6 days and justifies shorter treatment durations [16].
Although many textbooks do not specify the optimal duration
[17], the latest learned society guidelines recommend limiting
treatment to 8 days, particularly when appropriate initial antibiotic
treatment is administered, and in the absence of isolated
nonfermenting gram negative bacilli [18,19,20]. Current recom-
mendations are mainly based on one single randomized prospec-
tive study related to late-onset VAP [11]. Our randomized,
controlled trial comparing 2 antibiotic regimens (8 days versus 15
days) for the treatment of patients with EOVAP who had been
ventilated for less than 8 days, was carried out to provide further
evidence on the best length of treatment in this ICU population.
Some of the results of these studies have been previously
presented [21,22].
Methods
The protocol for this trial and supporting consort checklist are
available as supporting information; see checklist S1 and protocol
S1.
Inclusion criteria
Patients included in the study were over the age of 18 and had
developed EOVAP under invasive mechanical ventilation. The
pneumonia was defined as having an early-onset if the patient had
been ventilated for more than 24 hours and less than 8 days
[23,24,25]. A EOVAP diagnosis was considered in the presence of
at least 2 or 3 of the following clinical criteria: temperature
$38.3uC, leukocyte count .10000/mm3, excessive purulent or
mucopurulent bronchial secretion; and the radiological criterion
described by Weinberg [26] (Table 1): increase of 2 points in
radiological score compared to chest x-ray on admission, or no
improvement of a maximum score (11 or 12) on admission. The
diagnosis of pneumonia was confirmed by bronchoalveolar lavage
(BAL) culture of $104 colony-forming units/ml for at least one
bacterial species.
Randomization for treatment duration (8 versus 15 days) was
carried out if the bacteria identified in significant concentrations in
the BAL samples were susceptible to the authorized antibiotics
while for streptococci, a low level resistance to aminoglycosides
was not taken into account (Figure 1). Randomization is allocated
in each centre by a dedicated randomization table. The assigned
treatment arm is communicated by fax at the latest at D5 by the
main investigator center.
The exclusion criteria are detailed in table 2. The study protocol
had received local ethics committee and CCPPRB (Comite
Consultatif de Protection des Personnes dans la Recherche
Biomedicale de Franche Comte, number 97/189) approval. Each
patient or a member of their family had signed an informed
consent form, and written informed consent was obtained from all
participants involved in the study.
Treatment initiation
Patients received immediate treatment, according to the
standardized severity criteria (Table 3) and direct bacteriological
results from BAL samples if available. If immediate antibiotic
treatment was initiated, only patients who had been receiving
appropriate treatment from the outset were included.
All patients included in the study were treated with beta-lactams
for 8 or 15 days combined with an aminoglycoside for the first 5
days (Table 4). In the event of a secondary pulmonary infection or
the development of extrapulmonary infections, all antibiotics could
be used according to the bacteriological data. Once the patient
had been included in the protocol, BAL samples were taken for
intubated patients prior to making any changes to antibiotic
treatment (Table 5).
Patients were followed up daily during hospitalization in ICU.
The onset of intercurrent adverse events associated with the
treatment was recorded throughout the follow up (Table 6). All
intercurrent infectious events were documented according to the
clinical orientation based on appropriate sampling.
Evaluation criteria
Primary criteria for evaluating recovery. The primary
endpoint of the present study was the clinical cure rate at day 21.
Complete clinical recovery was determined by the absence of the
following criteria: death, septic shock (except when associated with
a documented non-respiratory infection), intercurrent adverse
event attributable to the protocol (or for which attributability to
the protocol could not be ruled out) requiring modified antibiotic
treatment (Table 6), and patients who relapsed. A relapse was
defined by a new infectious pulmonary event caused by the same
pathogen identified in the initial BAL fluid (regardless of its
susceptibility profile), associated with clinical and radiological signs
of nosocomial pneumonia (occurring $4 days of treatment) or a
worsening of 2 points of the baseline SOFA score.
Secondary criteria. The study focused on establishing the
determinants of clinical response on day 21: incidence of
secondary nosocomial infections; number of patients on antibiotic
treatment; total number of days of antibiotic treatment; duration
of MV; number of patients still under ventilation; number of
patients still in ICU; length of stay in ICU on day 21; and
mortality rate at 3 months. The following set of complementary
results enabled a better characterization of the study cohorts:
isolated pathogens; frequency of positive hemocultures; and
proportion of patients receiving first-line or secondary treatment
(Table 3).
Table 1. Radiologic score by Weinberg [26].
By quadrant:
0: normal
1: interstitial infiltrate
2: non-confluent cellular infiltrate
3: condensation
Total: sum scores of each of the 4 quadrants
doi:10.1371/journal.pone.0041290.t001
8 versus 15 Day Treatment in VAP
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Statistical analysis
The trial was designed to show equivalence in the clinical
response rates between the 2 treatment groups. A sample size of
220 patients was determined to be adequate to demonstrate
equivalence with a power of 80% and a basal response rate of
90%. The limits of the 95% confidence interval (CI) for the
difference between the response rates in the 2 treatments groups
were calculated, and the equivalence accepted if it did not exceed
10%.
Comparisons of baseline patient characteristics and secondary
criteria between the 2 cohorts were performed using the t-test for
continuous variables and the chi-square test or Fisher’s exact test
for categorical variables.
The efficacy analysis was conducted using an intent-to-treat
approach. Difference (d) and odds-ratio (OR) of response rates and
their 95% CIs were used to test the equivalence between the 2
cohorts [28,29].
All P values were two-sided. Data are presented as mean values
with the standard deviation in brackets for normal distribution
variables, and as median and quartile values for others (SAS
institute inc. USA version 9.1).
Figure 1. Design of the study governing inclusion of a new patient according to BAL bacteriological results and follow up criteria.
doi:10.1371/journal.pone.0041290.g001
Table 2. Exclusion criteria.
Patients with another source of infection on the day of BAL, except urinary infections with high susceptibility to the study antibiotics
Patients having received curative antibiotics, either following suspected pneumonia or during the 3 days prior to this suspicion, with the exception of surgical antibiotic
prophylaxis (defined according to consensus conference) [27]
Patients having received first-line treatment with antibiotics prohibited in this study
Patients with a known allergy to the antibiotics used in the study
Patient participating in another evaluative study
Other exclusion criteria:
-pregnancy,
-cystic fibrosis,
-acquired, induced or congenital immunodeficiency,
-leukopenia ,1000 GB/mm3,
-neutropenia ,500 PN/mm3,
-purulent pleurisy or pulmonary abscess at the time of pneumonia diagnosis.
doi:10.1371/journal.pone.0041290.t002
8 versus 15 Day Treatment in VAP
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Results
Patient characteristics
225 patients (109 in the 15 d cohort and 116 in the 8 d cohort)
were included and evaluated in 13 different centers over a period
of 4 years from 1998 to 2002, and 6 of the centers recruited 96%
of patients (figure 2). The patients’ baseline characteristics were
comparable in the 2 groups (Table 7). The cause of coma was
traumatic in 38.9% and 40.5% of patients in the 15 d and 8 d
cohorts respectively.
Bacteriology
There were no significant differences between the proportions
of gram-negative bacilli (p = 0.32) and gram-positive cocci
(p = 0.65) from one group to the other. 32.9% of the pathogens
isolated in BAL samples were MSSA in the 15 d cohort, and
28.2% in the 8 d cohort. The samples were multimicrobial for
54.1% of patients in the 15 d cohort and 37.9% of patients in the
8 d cohort (p = 0.03), but the antibiotics used were active on all
pathogens. The bacteria isolated in the BAL samples are shown in
Table 8. For 2 (15 d cohort) and 3 (8 d cohort) patients, several
strains of MSSA were isolated in the BAL fluid. One MSSA
pathogen was identified in the BAL samples of 58 patients in the
15 d cohort and 45 patients in the 8 d cohort (p = 0.35).
18 patients (8 in the 15 d cohort, 10 in the 8 d cohort) presented
at least one positive hemoculture during the 24 hours of BAL
sampling. For 7 of these patients, the isolated pathogen in the
hemoculture was the same as in the BAL fluid. We found 5 MSSA,
1 pneumococcus and 1 Escherichia coli. For the remaining 11 patients,
the pathogen was not isolated in the BAL fluid or in an another
Table 3. Indications for antibiotic treatment before bacteriology results.
Treatment can commence immediately in the presence of at least one of the following organ/system failures combined with sepsis:
Respiratory:
PaO2/FiO2 ,300
Cardiovascular (at least one of the following criteria in the absence of hypovolemia):
SAP ,90 mmHg or decrease .40 mmHg with signs of peripheral hypoperfusion
Use of inotropic or vasopressor drugs to maintain SAP .90 mmHg
Renal (at least one of the following criteria in the absence of chronic renal failure):
Creatinine levels .300 mmol/l
Diuresis ,500 ml/24 h or 180 ml/8 h
Patients requiring dialysis
Central Nervous (at least one of the following criteria):
Glasgow score ,6 (in absence of sedation)
Sudden onset of confusional syndrome
Hepatic (at least one of the following criteria):
Bilirubin .100 mmol/l
Alkaline phosphatase .63 normal level
Coagulation (at least one of the following criteria):
Hematocrit 20%
Leukocytosis ,2000/mm3
Platelets ,40 000/mm3
doi:10.1371/journal.pone.0041290.t003
Table 4. Treatments authorized in the study.
Beta-lactams:
Amoxicillin plus clavulanic acid (2 g63/d for 3 days, then 1 g63/d)
Ceftriaxone (2 g/d for3 days, then 1 g/d)
Cefotaxime (2 g63/d for 3 days, then 1 g63/d)
Aminoglycosides*:
Tobramycin (loading dose: 6 mg/kg/d, then maintenance dose: 5 mg/kg/d);
Netilmicin (9 mg/kg/d, then maintenance dose 7 mg/kg/d);
Dibekacin (6 mg/kg/d, then maintenance dose 5 mg/kg/d).
*Aminoglycosides were administered in a single dose with a loading dose on
the first day of treatment. The dose was adapted in the event of renal failure.
doi:10.1371/journal.pone.0041290.t004
Table 5. Definition of secondary infections requiring the
initiation of antibiotic treatment for more than 48 hours.
Bacteremia:
1 positive hemoculture
or 2 hemocultures positive for Staphylococcus epidermidis
Catheters:
Bacteria culture on catheter tip $103 cfu/ml
Urine:
Culture $105 cfu/ml and .10 PN/field
Pulmonary:
Culture $104 cfu/ml on BAL
Others:
Sinusitis: positive sinus puncture
Puncture sites: positive local samples
doi:10.1371/journal.pone.0041290.t005
8 versus 15 Day Treatment in VAP
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focus of infection. We found 6 Staphylococcus epidermidis or negative
coagulase, 1 enterococcus, 3 streptococci and 1 MSSA. The mortality
rate for patients with positive hemoculture did not differ from the
overall study population (p= 0.82; Fischer’s exact test).
Treatment duration and compliance
Immediate treatment was initiated following BAL in 77 (71%)
and 81 (70%) patients in the 15 d and 8 d cohorts respectively.
The mean durations for first-line treatment were 13.1 (3.6) days
and 7.8 (1.6) days for the 15 d and 8 d cohorts respectively
(p,0.01).
Principal criteria
According to our judgment criteria, a total of 191 out of the 225
patients (84.9%) included in the study were cured; 92 out of 109
(84.4%) in the 15 d cohort and 99 out of 116 (85.3%) in the 8 d
cohort (d = 0.9%, OR=0.929). 95% two-sided CIs for difference
and OR were [28.4% to 10.3%] and [0.448 to 1.928]
respectively. Taking into account the limits of equivalence (10%
for difference and 2.25 for OR), the protocol objective of
demonstrating equivalence between the 2 treatment regimens
was fulfilled.
Secondary objectives
The mortality rate evaluated on day 21 was comparable in the 2
cohorts. 19 patients died, 9 (8.3%) in the 15 d cohort and 10
(8.6%) in the 8 d cohort (p = 0.92). The median delay between
antibiotic treatment initiation and death was also comparable in
the 2 cohorts; 11.8 (5.7) days and 10.7 (4.8) days for the 15 d and
8 d cohorts respectively (p = 0.66). At 3 months, 88% of all
patients had been evaluated. Out of 96 patients in the 15 d and
102 patients in the 8 d cohort, the mortality rate was almost
identical: 17.4% and 17.2% respectively (p = 0.99).
Nine patients experienced an adverse event requiring treatment
modification: 5 in the 15 d and 4 in the 8 d cohort. The cause of
the event was cutaneous in 4 cases, digestive (C. difficile) in 3 cases
and hepatic in 2 cases. 19 patients experienced septic shock (10 in
the 15 d and 9 in the 8 d groups), 17 in the absence of new
infectious event, and 2 in the presence of an undocumented
infectious intercurrent event.
Eight patients experienced a relapse of the initial pulmonary
infection with isolation of the same pathogen in pulmonary
samples; 2 in the 15 d and 6 in the 8 d cohort (NS). One
pneumococcus and 1 methicillin-resistant Staphylococcus aureus (MRSA)
pathogen (initial presence of 1 MSSA pathogen) persisted in the
15 d cohort. One Haemophilus, 1 Serratia, 3 MSSA and 1 MRSA
(initial presence of 1 MSSA) persisted in the 8 d cohort. For both
durations, the median delay between treatment initiation and
relapse diagnosis was 11.6 days (min= 7; max= 18).
Table 6. Definition of intercurrent adverse events.
Definitions
Acute renal failure (creatinemia62 compared to pre-treatment value):
Serious: anuria
Persistent diuresis
Cutaneous complications:
Serious: Lyell’s syndrome
Other
Digestive complications:
Serious: pseudomembranous colitis
Other
Hematologic complications:
Serious: anemia, leukopenia and/or grade 3 or 4* thrombopenia
Other grades
Allergic complications
Serious: anaphylactic shock
Other
Other (hepatitis, encephalopathy, pneumopathy)
*World Health Organisation rating.
doi:10.1371/journal.pone.0041290.t006
Figure 2. Data regarding number of patients included, treated according to protocol and followed up at 21 and 90 days.
doi:10.1371/journal.pone.0041290.g002
8 versus 15 Day Treatment in VAP
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Table 7. Admission characteristics of the study patients according to the duration of antibiotic treatment.
15 days 8 days
N=109 N=116
n (%) n (%)
m± sd m± sd p Values
Sex-ratio 2.4 2.4 0.99
Age (years) 48.2619.5 49.6619.6 0.59
Weight (kg) 73.1616.4 73.6617.0 0.80
Origin
-hospital 33 (30.3) 35 (30.2) 0.99
-home 76 (69.7) 81 (69.8)
Reason for admission
-medical 63 (57.8) 59 (50.9) 0. 35
-surgical (scheduled) 2 (1.8) 0 0.23
-surgical (emergency) 6 (5.5) 12(10.3) 0.22
-post-trauma 42 (38.5) 47(40.5) 0.22
Coma
-RTA* 42 (38.9) 47 (40.5) 0.89
-toxic 11 (10.2) 6 (5.2) 0.21
SAPS{ II 39.7612.5 39.2613.4 0.76
Delay between:
-hospital and ICU{ admission
0 day 76 (69.7) 79 (68.1) 0.82
1,D,3 days 7 (6.4) 10 (8.6)
more than 4 days 26 (23.9) 27 (23.3)
-hospital admission and intubation (days) 1.062.9 2.168.9 0.22
Median 0 0
IQR 1 1
-ICU admission and intubation (days) 0.1361.4 0.4962.8 0.22
Median 0 0
IQR 0 0
-Intubation and BAL1 (days) 3.461.8 3.561.9 0.59
Median 3 3
IQR 2 3
Clinical Criteria for Pneumonia
-Fever 98 (89.9) 103 (88.8) 0.79
-Leukocytosis 69 (63.3) 78 (67.2) 0.54
-Purulent secretion 108 (99.1) 113 (97.4) 0.62
-Radiologic score 4.36 (1.9) 4.55 (2.1) 0.48
Treatment
Beta-lactam
-Amoxicillin+Clav. Ac. 39 (35.8) 48 (41.4) 0.41
-C3G** 70 (64.2) 68 (58.6)
Aminoglycoside
-Netilmicin 35 (32.1) 37 (31.9) 0.97
-Tobramycin 74 (67.9) 79 (68.1)
Abbreviations:
*RTA: road traffic accident;
{SAPS: simplified acute physiological score;
{ICU: intensive care unit;
1BAL: bronchoalveolar lavage;
**3GC: third generation cephalosporin.
doi:10.1371/journal.pone.0041290.t007
8 versus 15 Day Treatment in VAP
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Secondary nosocomial infections during the 21 days after
randomization
A secondary infection was diagnosed in 19.3% of patients in the
15 d cohort and 35.3% of patients in the 8 d cohort (p,0.01)
(Table 9). Comparisons between patients with and without
secondary infections are depicted in table 10. Patients presented
more pulmonary infections than extrapulmonary infections. 116
BAL were performed during the follow-up. 71 BAL done after
initiation of the treatment were negative (26 for the 15 days and 45
for the 8 days arms, p = 0.01). There was no difference in the
proportion of patients with a negative BAL, respectively 24
(22.0%) and 33 (28.7%) for the 15 and 8 days groups (p = 0.27).
The isolated bacteria are reported in table 11. In patients in whom
antibiotics were not started immediately, we also did not find any
mortality difference at day 21. We compared the superinfection
rate in patients receiving either a third generation cephalosporin
or amoxicilline-clavulanic acid. Overall, there was no difference
(respectively 28% and 26.4%). We analysed this superinfection
rate according to the length of treatment and to the type of
antibiotic (third generation cephalosporin or amoxicilline-clavu-
lanic acid) and did not find any significant difference (15 days
group respectively 20% and 18%; 8 days group respectively 37%
and 33%).
Taking into consideration the onset of a secondary infection as
an added failure criterion, the percentages of cured patients
(clinical success) were 64.2% in the 15 d cohort and 49.1% in the
8 d cohort (d = 15.1%). 95% two-sided CI for difference was
[2.3% to 27.9%]. Taking into account the limit of equivalence
(10%), equivalence between the 2 treatments was rejected.
Other secondary criteria
Sixty-four patients in the 15 d cohort (58.7%) and 66 (56.9%) in
the 8 d cohort had been discharged alive from the ICU by day 21.
The mean duration of hospitalization in ICU was 15.7 (5) days in
the 15 d cohort and 15.9 (5.1) days in the 8 d cohort (p = 0.82).
The length of stay in ICU after treatment initiation was 11.9 (4.4)
days in the 15 d cohort and 11.3 (3.7) days in the 8 d cohort
(p = 0.42). The mean duration of intubation in ICU was 13.4 (5.9)
days in the 15 d cohort and 13.6 (5.3) days in the 8 d cohort
(p = 0.81). The number of patients intubated at day 21 did not
differ between the 2 groups (36 in the 15 d cohort and 40 in the
8 d cohort; p = 0.88).
The mean duration of antibiotic treatment (all molecules
grouped together) during the 21 days of follow up was 15.4 (3.4)
days for the 15 d and 11.3 (4.7) days for the 8 d cohort (p,0.01).
The median durations of antibiotic treatment during the 21 days
of follow up were 15 and 8 days respectively. The number of
patients still on antibiotics on day 21 was significantly different
between both groups; 20 patients in the 15 d cohort and 39 in the
8 d cohort (p = 0.01). Among these patients, 13 in the 15 d cohort
and 18 in the 8 d cohort had left ICU (p= 0.41).
Discussion
The results of this prospective, randomized study showed that
15 and 8 days of initially appropriate antibiotic treatment for
EOVAP were equivalent according to the rate of complete clinical
recovery. Additionally, 21 and 90-day mortality rates as well as
durations of mechanical ventilation and of ICU stay were not
different between both strategies. However, the rate of secondary
infections was higher in the 8 d cohort than in the 15 d cohort,
resulting in a lower rate of clinical cure in the 8 d strategy when
including the occurrence of a secondary infection [11]. Despite
this difference, the number of days of antibiotic treatment was
lower in the 8 d cohort and around 50% of the secondary
infections remained sensitive to the first-line treatment.
In the present study, VAP was defined as early when it occurred
between 1 and 8 days after initiation of mechanical ventilation.
Moreover, antibiotic choice was protocolized using quite limited-
spectrum antibiotics and appropriate first-line antibiotics were a
pre-requisite for patient inclusion in our study. Compared to our
definition, early onset pneumonia has been commonly defined as
occurring in the first 4 days. However, extended periods of 5 to 7
days have been used in the literature [9,23,24,25,31]. To note,
94% of our patients were included in the 6 days following
initiation of mechanical ventilation. The bacteriology of EOVAP
rarely consists of multiresistant pathogens. Microbiological data
from BAL fluid of our patients confirmed this with a strong
predominance of MSSA, streptococci, Haemophilus and enter-
obacteriacae species. Although the isolation of resistant bacteria
has been reported in EOVAP [8,9,32], the percentage of resistant
bacteria only accounted for 13% of those isolated in a recent study
Table 8. Microbiology of pneumonia according to the
treatment group.
15 days* 8 days*
N=182 N=170
n (%) n (%) p Values
Gram+ cocci 104 (57%) 93 (54.7%) 0.65
Staphylococcus 60 48 0.34
-MSSA 57 46
-MSCNS 3 2
Streptococcus 44 45
-Pneumoniae 22 23
-Other 21 22
-Enterococcus 1 0
Gram2 cocci 4 2
-Neisseria 3 2
-Other 1 0
Gram+ bacilli 4 1
-Corynebacterium 4 1
Gram2 bacilli 70 73 0.32
Enterobacteria 23 20 0.46
-Escherichia coli 12 10
-Proteus 6 1
-Serratia 1 0
-Citrobacter 0 3
-Klebsiella 2 4
-Enterobacter 2 1
-Hafnia 0 1
Haemophilus 43 52 0.41
Chryseomonas 1 0
Branhamella 2 0
Moraxella 0 1
Pasteurella 1 0
Anaerobes 0 1
*The number of bacteria isolated in the BAL sample is .1 for 59 patients in the
15 days and 44 patients in the 8 days cohorts.
doi:10.1371/journal.pone.0041290.t008
8 versus 15 Day Treatment in VAP
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[7], and a strategy using limited-spectrum antibiotics allowed for
appropriate treatment in 80% of cases of EOVAP [33,34]. To
note, polymicrobial samples were more common in our 15 d
cohort. The reason for this is not clear, but the sensitivity of the
bacteria to the initial treatment means that it probably had no real
impact. As for all our patients, a polymicrobial incidence of
around 50% was reported during VAP. Combes et al found that
the epidemiology and outcomes of patients with monomicrobial
and polymicrobial VAP did not differ significantly [35]. In our
study, polymicrobial samples were not detrimental to recovery.
Until recently, recommendations for treatment duration of VAP
were based only on the advice of experts [4,18,30] as there was no
prospective, randomized study available when the present trial was
initiated. Chastre et al. found no clear advantage in prolonging
antibiotic treatment to 15 days compared with 8 days when
treating late-onset VAP [11]. Our data strongly suggest that a 8-
day treatment of EOVAP enables recovery in the same
proportions as a 15-day regimen using the same clinical and
microbiological cure criteria than those used in other studies
[36,37,38]. Equivalence was obtained according to the criteria that
we defined at first, in particular that the onset of a secondary
pulmonary infection did not exclude the possibility that the
primary infection had been cured. These data confirm recom-
mendations for reducing treatment to 7–8 days for EOVAP
[4,12,16,39]. Moreover, the reception of negative microbiological
samples [16], as well as the clinical response evaluated by
composite scores [12,40] may help to securely shorten the
duration of antibiotic treatment of VAP. Recently, the implemen-
tation of an antibiotic protocol for VAP including these tools has
indeed been associated with a reduction of antibiotic treatment
duration from 10.1 (8) to 6.2 (3.3) days associated with a reduction
in the duration of mechanical ventilation [31]. These objectives
have now been extended to early- and late-onset pneumonia by
learned societies [18,19,20] except if the etiologic agent was P.
aeruginosa or an Acinetobacter species which carry a greater risk of
relapse. Prolonged antibiotic therapy may also be justifiable in
cases of pulmonary infections caused by MRSA due to the delayed
response to treatment [41], and the increased risk of relapse [42].
Further research is required to determine if a 8-day treatment of
resistant bacteria EOVAP is safe since these cases have been
excluded from the present study.
In our study, the rate of secondary pulmonary and extrapul-
monary infections was significantly higher in the 8 d cohort. The
risk of acquiring a nosocomial infection is high during the first few
days following admission to ICU [43,44], and patients frequently
develop several infections simultaneously or close together [44,45].
An early but short treatment of VAP could therefore lead to a
higher rate of infections rapidly unmasked after antibiotic stop or
treated too shortly. Indeed, a majority of superinfections in the 8d
cohort occurred in the few days following the end of antibiotic
treatment. In the multicenter trial of 8 vs 15 days of antibiotic
treatment for late onset VAP by Chastre et al [11], neither relapses
nor superinfection rates were different between both strategies.
Several reasons related to the type of infection and to their
treatment may explain this difference. First, whereas in this latter
study, over 80% of patients had received curative antibiotics in the
15 days prior to inclusion, this situation did not apply to any of our
patients. Moreover, broad spectrum antibiotics were used in the
Chastre et al [11] study according to the isolated bacteria. Finally,
a combination of antibiotics including an aminoglycoside was used
in more than 90% on day 1 and was still administered on day 8 in
more than 30% of patients while in our study, we protocolized the
use of narrow spectrum antibiotics and aminoglycosides were
stopped on day 5.
We did not recommend using fluoroquinolones and proposed
an aminoglycoside treatment with a limited duration, identical in
the 2 cohorts. Nevertheless, the use of combination therapy is
debatable considering the bacteria expected in EOVAP. Indeed, a
recent trial suggested that monotherapy is associated with similar
outcomes compared with combination therapy in patients who
have suspected late VAP and who are at low risk for difficult-to-
treat gram-negative bacteria, [46]. This strategy would probably
be applicable to our patients, excepted in patients with septic
shock.
Several limitations were apparent in our study. First, although it
was planned, it has not been possible to accurately quantify the
number of patients who were not included in the study, as well as
the microbiologic characteristics of their VAP. Nevertheless, the
non-inclusion of the most critically-ill patients cannot be the main
reason. Indeed, patients with a deep source of infection (abscess or
purulent pleurisy) as well as immunodeficient patients were
excluded from the study. Moreover, mean SAPS II was 39, 70%
of the study population had 2 organ failures and 18 patients
presented with bacteriemia. Second, except for mortality rate,
follow-up was limited to 21 days. However, only 31% of patients
were still hospitalized on day 21, what limits the interest and
validity of a longer follow-up. Third, although this study enrolled
patients in 13 centers, 6 of them included 96% of patients.
Table 9. Patients with documented secondary infections.
15 days 8 days p Value
N=109 N=116 **
Patient, n (%) 21(19.3) 41(35.3) ,0.01
Infections, n (%) 22 (20.2) 46 (39.7) ,0.01
Origin Pulmonary, n (%) 15 (13.8) 30 (25.8) 0.03
Sensitive to first-line treatment
-S* bacteria, n(%) 12 (54.5) 28 (60,8) 0.76
-R{ bacteria, n(%) 10 (45.5) 18 (39.2)
Secondary infection delay occurrence (day) 11.665.6 10.564.9 0.57
Abbreviations:
*sensitive,
{resistant,
**Fischer exact test.
doi:10.1371/journal.pone.0041290.t009
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However, 5 patients were included in low inclusion rate centers in
each arm. Moreover, randomisation was processed by center to
avoid any center effect. Fourth, patients were treated with a
combined therapy. While the aminoglycosides are not great
pneumonia drugs, they clearly have some benefit resulting in a
synergistic effect with beta-lactams and a larger antibiotic
spectrum. As a consequence, aminoglycosides might have skewed
the results toward equivalence.
In conclusion, our study enabled us to recommend reduced
treatment duration of 8 days for early-onset VAP, while respecting
the contra indications. The higher rate of secondary infections in
the 8 days than in the 15 days treatment strategy highlights the
Table 10. Comparisons between patients with and without secondary infections.
All population 15 days 8 days
N=225 N=109 N=116
n (%) n (%) n (%)
m± sd m± sd m± sd
S NoS p S NoS p S NoS p
N=62 N=163 Values N=21 N=88 Values N=41 N=75 Values
Origin
-hospital 22(35.5) 46(28.2) 0.29 7(33.4) 26(29.6) 0.74 15(36.6) 20(26.7) 0.27
-home 40(64.5) 117(71.8) 14(66.7) 62(70.5) 26(63.4) 55(73.3)
Reason for admission
-medical 32(53.3) 90(55.2) 0.80 11(57.9) 52(59.1) 0.92 21(51.2) 38(50.7) 0.95
-surgical (scheduled) 0(0.0) 2(1.2) 1 0(0.0) 2(2.3) 1 0(0.0) 0(0.0)
-surgical (emergency) 6(9.84) 11(6.75) 0.41 1(5.0) 4(4.55) 1 5(12.2) 7(9.3) 0.75
-post-trauma 26(42.6) 63(38.7) 0.59 9(45.0) 33(37.5) 0.53 17(41.5) 30(40.0) 0.88
Coma toxic 1(1.6) 16(9.82) 0.05 1(5.0) 10(11.4) 0.69 0(0.0) 6(8.0) 0.09
SAPS{ II 38.5613.0 39.8613.0 0.50 44.5610.8 38.5612.7 0.05 35.4612.9 41.2613.3 0.02
Delay between
-hospital and ICU{
admission (days)
0,961.8 1.467.1 0.35 0.862.2 0.962.6 0.83 0.961.6 2610 0.35
-hospital admission and
intubation (days)
1.263.6 1.767.2 0.45 1.064.1 1.162.6 0.99 1.363.4 2.6610.2 0.32
-ICU admission and
intubation (days)
0.363.1 0.361.9 0.98 0.262.2 0.161.3 0.73 0.463.5 0.562.4 0.77
-Intubation and BAL1 (days) 3.761.7 3.461.9 0.27 3.761.9 3.361.7 0.40 3.761.5 3.462.1 0.49
Clinical Criteria for
Pneumonia
-Fever 53(85.5) 148(90.8) 0.25 19(90.5) 79(9.8) 1 34(82.9) 69(92.0) 0.22
-Leukocytosis 41(66.1) 106(65.0) 0.88 15(71.4) 54(61.4) 0.39 26(63.4) 52(69.3) 0.52
-Purulent secretion 60(96.8) 161(98.8) 0.30 20(95.2) 100(100.0) 0.19 40(97.6) 73(97.3) 1
-Radiologic score 4.862.5 4.361.8 0.25 4.862.5 4.361.7 0.37 4.762.5 4.561.8 0.54
Treatment
Beta-lactam
-Amox.+Clav.Ac. 23(37.1) 64(39.3) 0.77 7(33.3) 32(36.4) 0.79 16(39.0) 32(42.7) 0.70
-C3G* 39(62.9) 99(60.7) 14(66.7) 56(63.6) 25(61.0) 43(57.3)
Aminoglycoside
-Netilmicin 19(30.7) 53(32.5) 0.79 6(28.6) 29(33.0) 0.7 13(31.7) 24(32.0) 0.97
-Tobramycin 43(69.4) 110(67.5) 15(71.4) 59(67.1) 28(68.3) 51(68.0)
First-line treatment 9.063 10.963.9 ,0.01 11.763.8 13.563.5 0.02 7.761.1 7.961.8 0.36
Antibiotic treatment** 15.864.7 12.364.1 ,0.01 18.962.6 14.563.0 ,0.01 14.364.8 9.763.7 ,0.01
Mortality 21 days 4(6.5) 15(9.2) 0.51 0(0.0) 9(10.2) 0.20 4(9.8) 6(8.0) 0.74
Abbreviations:
{SAPS: simplified acute physiological score;
{ICU: intensive care unit;
1BAL: bronchoalveolar lavage;
*3GC: third generation cephalosporin;
**all molecules grouped together.
doi:10.1371/journal.pone.0041290.t010
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importance of rigorous clinical monitoring and the possible
interest of biological markers for securing this strategy.
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